Analysis of President Trump's Claims on Prescription Drug Pricing

During the 2026 State of the Union address, President Donald Trump asserted that he is "ending the wildly inflated cost of prescription drugs" through his recently enacted most-favored-nation agreements. He claimed that Americans would now pay the lowest prices for prescription drugs globally, a statement that has been met with skepticism from various analysts and critics. Trump's executive order, signed in May 2025, directed the Department of Health and Human Services (HHS) to communicate price targets to pharmaceutical manufacturers, aiming to align U.S. drug prices with those in comparably developed nations.

ReasonMEMO: Trump and Republicans in Congress Have Done Nothing to Address Drug Prices — Protect Our Care

Critics argue that Trump's claims are misleading. Michael F. Cannon from the Cato Institute noted that HHS lacks the authority to impose price controls on private pharmaceutical purchases. Furthermore, despite Trump's assertions that 16 pharmaceutical companies had agreed to lower prices, reports indicated that these companies raised their list prices in January 2026, contradicting the administration's narrative.

Reason

The organization Protect Our Care highlighted that Trump's administration has historically cut over $1 trillion from Medicaid and the Affordable Care Act, which they argue has exacerbated healthcare costs for millions of Americans. They contend that Trump's promises to reduce drug prices are mere distractions from his administration's failures in healthcare policy.

MEMO: Trump and Republicans in Congress Have Done Nothing to Address Drug Prices — Protect Our Care

The Inflation Reduction Act, passed under Trump's predecessor, allowed Medicare to negotiate prices for certain drugs, a move that Trump and his allies opposed. Critics assert that while Trump attempts to take credit for any savings resulting from these negotiations, his administration has actively worked to undermine them. For instance, Trump's signing of an $8.8 billion bailout exempted top-selling drugs from Medicare price negotiations, delaying potential relief for patients reliant on these medications.

MEMO: Trump and Republicans in Congress Have Done Nothing to Address Drug Prices — Protect Our CareReason

In response to Trump's claims, Protect Our Care stated, "No matter what Trump says, he can’t hide from his failed record on drug prices." They emphasized that Trump's executive order appears to favor pharmaceutical companies rather than providing tangible benefits to patients. Additionally, industry analysts have described Trump's "TrumpRx" initiative as ineffective, suggesting it serves more as a publicity stunt than a genuine effort to lower drug costs.

MEMO: Trump and Republicans in Congress Have Done Nothing to Address Drug Prices — Protect Our Care

There are discrepancies in the reported effectiveness of Trump's drug pricing initiatives. While the administration claims significant price reductions, independent analyses indicate that drug prices have continued to rise. The lack of concrete evidence supporting Trump's assertions raises questions about the actual impact of his policies on drug affordability.

MEMO: Trump and Republicans in Congress Have Done Nothing to Address Drug Prices — Protect Our Care

• “I got it done under my just-enacted most-favored-nation agreements,” — President Donald Trump

Reason

• “HHS does not have the power to 'impose' price controls on private pharmaceutical purchases.” — Michael F. Cannon, Cato Institute

Reason

• “If this is all that President Trump does on drug pricing, it is likely a win for the pharmaceutical industry and should serve as a clearing event,” — Chris Meekins, Industry Analyst

MEMO: Trump and Republicans in Congress Have Done Nothing to Address Drug Prices — Protect Our Care

In summary, while President Trump's administration has made claims regarding lowering prescription drug prices, significant skepticism remains regarding the actual effectiveness and intent behind these policies. Critics argue that the administration's actions have often favored pharmaceutical companies over the needs of American patients.

Reason